(S)-N-(4-fluorobenzyl)-6,7-dihydroxy-1,2,3,4-tetrahydroisoquinoline-3-carboxamide

ID: ALA5176290

Chembl Id: CHEMBL5176290

PubChem CID: 168275791

Max Phase: Preclinical

Molecular Formula: C17H17FN2O3

Molecular Weight: 316.33

Associated Items:

Names and Identifiers

Canonical SMILES:  O=C(NCc1ccc(F)cc1)[C@@H]1Cc2cc(O)c(O)cc2CN1

Standard InChI:  InChI=1S/C17H17FN2O3/c18-13-3-1-10(2-4-13)8-20-17(23)14-5-11-6-15(21)16(22)7-12(11)9-19-14/h1-4,6-7,14,19,21-22H,5,8-9H2,(H,20,23)/t14-/m0/s1

Standard InChI Key:  JTPKXEPYXQQDKY-AWEZNQCLSA-N

Alternative Forms

  1. Parent:

    ALA5176290

    ---

Associated Targets(Human)

TRPV1 Tclin Vanilloid receptor (8273 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Associated Targets(non-human)

Trpm8 Transient receptor potential cation channel subfamily M member 8 (889 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Topical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Calculated Properties

Molecular Weight: 316.33Molecular Weight (Monoisotopic): 316.1223AlogP: 1.57#Rotatable Bonds: 3
Polar Surface Area: 81.59Molecular Species: NEUTRALHBA: 4HBD: 4
#RO5 Violations: HBA (Lipinski): 5HBD (Lipinski): 4#RO5 Violations (Lipinski):
CX Acidic pKa: 9.20CX Basic pKa: 7.06CX LogP: 1.94CX LogD: 1.77
Aromatic Rings: 2Heavy Atoms: 23QED Weighted: 0.65Np Likeness Score: -0.37

References

1. Di Sarno V, Giovannelli P, Medina-Peris A, Ciaglia T, Di Donato M, Musella S, Lauro G, Vestuto V, Smaldone G, Di Matteo F, Bifulco G, Castoria G, Migliaccio A, Fernandez-Carvajal A, Campiglia P, Gomez-Monterrey I, Ostacolo C, Bertamino A..  (2022)  New TRPM8 blockers exert anticancer activity over castration-resistant prostate cancer models.,  238  [PMID:35598411] [10.1016/j.ejmech.2022.114435]

Source